|
Sign In to gain access to subscriptions and/or personal tools.
|
Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
J Alvarez-Nemegyei
A Cobarrubias-Cobos
F Escalante-Triay
J Sosa-Muüoz
Rheumatology Department, Centro Médico Nacional ‘El Fenix’, Mérida, Yucatán
J M Miranda
L J Jara
Rheumatology Department, Centro Médico Nacional La Raza. Instituto Mexicano del Seguro Social, Mexico City, Mexico
The objective of this study was to investigate the efficacy and safety of bromocriptine (BRC) as an adjunct to conventional treatment in systemic lupus erythematosus (SLE). A prospective, doubleblind, randomized, placebo-controlled study compared BRC at a fixed daily dosage of 2.5 mg with placebo. Patients were followed for 2–17 months (mean 12.5 months). Disease activity was assessed using the SLE Disease Activity Index (SLEDAI), numbers of flares were recorded, and serum prolactin (PRL) levels were obtained at intervals during the study. Patients were allowed to take prednisone and immunosuppressive drugs.
Sixty-six patients with SLE entered the study. Thirty-six were treated with BRC, and 30 controls received placebo. Sixteen patients were removed from the study during the treatment period: five in each group left the study because of adverse effects, five became pregnant, and one patient who took placebo died with central nervous system lupus. Four patients in the BRC treatment group and three patients in the placebo group moved away or stopped coming for study visits for unknown reasons, and were lost to follow-up during the course.
At entry, serum PRL was (mean–s.d.) 24.8 ng/ml–18.4 in the BRC treatment group. This value fell to 5.8–9.0 after 12 months of treatment. Corresponding PRL values in controls were 23.7–22.1 pretreatment and 20.3–14 after 12 months. PRL levels in BRC-treated subjects were significantly lower than levels in control subjects after 3, 6, 9, and 12 months of treatment. The SLEDAI score on the fifth protocol visit was decreased significantly in the BRC group vs controls: 0.9–1.4 vs 2.6–4.5 (P < 0.05). Although the absolute number of flares in each group was similar, the mean number of flares/patient/month was decreased significantly in the BRC group compared to the control group (0.08–0.1 vs 0.18–0.2, P = 0.03).
Long term treatment with a low dose of BRC appears to be a safe and effective means of decreasing SLE flares in SLE patients.
Key Words: prolactin • bromocriptine • systemic lupus • erythematosus
Lupus, Vol. 7, No. 6,
414-419 (1998)
DOI: 10.1191/096120398678920334
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Y. Yuen and J. E. Pope
Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials
Rheumatology,
September 1, 2008;
47(9):
1367 - 1372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhang, R. Sun, and Z. Tian
Human Prolactin Promotes Human Secondary Immunoglobulin Response in Human/SCID Mouse Chimeras
Clin. Vaccine Immunol.,
January 1, 2007;
14(1):
60 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Leanos-Miranda and G. Cardenas-Mondragon
Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity
Rheumatology,
January 1, 2006;
45(1):
97 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Kamal and W. J. Jusko
Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays
J. Clin. Pharmacol.,
September 1, 2004;
44(9):
1034 - 1045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Garcia, M E Colombani-Vidal, C C Zylbersztein, A Testi, J Marcos, A Arturi, J Babini, and H E Scaglia
Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus
Lupus,
August 1, 2004;
13(8):
575 - 583.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. J. Petro
Treatment of systemic lupus erythematosus with bromocriptine
Lupus,
April 1, 2002;
11(4):
266 - 267.
[PDF]
|
|
|
|
|
|
|
R. H. Straub, J. Georgi, K. Helmke, P. Vaith, and B. Lang
In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers
Rheumatology,
April 1, 2002;
41(4):
423 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S E Walker and L.-y. Yu-Lee
Overview: prolactin and autoimmunity
Lupus,
October 1, 2001;
10(10):
659 - 659.
[PDF]
|
|
|
|
|
|
|
A Stevens, D W Ray, J Worthington, and J R. Davis
Polymorphisms of the human prolactin gene--implications for production of lymphocyte prolactin and systemic lupus erythematosus
Lupus,
October 1, 2001;
10(10):
676 - 683.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R W McMurray
Prolactin in murine systemic lupus erythematosus
Lupus,
October 1, 2001;
10(10):
742 - 747.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S E Walker
Bromocriptine treatment of systemic lupus erythematosus
Lupus,
October 1, 2001;
10(10):
762 - 768.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A M Jacobi, W Rohde, M Ventz, G Riemekasten, G-R Burmester, and F Hiepe
Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity
Lupus,
August 1, 2001;
10(8):
554 - 561.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Hrycek, P Cieslik, J Tustanowski, S Nowak, and P Jedynak
Selected serum cytokines in systemic lupus erythematosus treated with quinagolide
Lupus,
June 1, 2001;
10(6):
424 - 430.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S E Walker
Treatment of systemic lupus erythematosus with bromocriptine
Lupus,
March 1, 2001;
10(3):
197 - 202.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A M Jacobi, W Rohde, H-D Volk, T Dorner, G-R Burmester, and F Hiepe
Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls
Ann Rheum Dis,
March 1, 2001;
60(3):
242 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Corzillius and S-C Bae
Methodological issues of corticosteroid use in SLE clinical trials
Lupus,
October 1, 1999;
8(8):
692 - 697.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L Mateo and J M Nolla
Prolactin in rheumatoid arthritis
Lupus,
March 1, 1999;
8(3):
251 - 251.
[PDF]
|
|
|
|
|
|
|
S E Walker, D Miller, D L Hill, and G R Komatireddy
Prolactin, a pituitary hormone that modifies immune responses: Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico
Lupus,
July 1, 1998;
7(6):
371 - 375.
[PDF]
|
|
|
|
|
